Pill Identifier App

Generic Renvela Availability

Renvela is a brand name of sevelamer, approved by the FDA in the following formulation(s):

RENVELA (sevelamer carbonate - for suspension;oral)

  • Manufacturer: GENZYME
    Approval date: February 18, 2009
    Strength(s): 2.4GM/PACKET [RLD]
  • Manufacturer: GENZYME
    Approval date: August 12, 2009
    Strength(s): 800MG/PACKET

RENVELA (sevelamer carbonate - tablet;oral)

  • Manufacturer: GENZYME
    Approval date: October 19, 2007
    Strength(s): 800MG [RLD]

Has a generic version of Renvela been approved?

No. There is currently no therapeutically equivalent version of Renvela available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Renvela. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Phosphate-binding polymers for oral administration
    Patent 5,667,775
    Issued: September 16, 1997
    Inventor(s): Holmes-Farley; Stephen Randall & Mandeville, III; W. Harry & Whitesides; George M.
    Assignee(s): GelTex Pharmaceuticals, Inc.
    Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.
    Patent expiration dates:
    • September 16, 2014
      Patent use: PHOSPHATE BINDING
  • Aliphatic amine polymer salts for tableting
    Patent 7,985,418
    Issued: July 26, 2011
    Inventor(s): Bhagat; Hitesh R. & Goldberg; Jeffrey M. & Harianawala; Abizer I. & Brenner; Louis
    Assignee(s): Genzyme Corporation
    The tablets, compositions and methods of the present invention, comprising a carbonate salt of an aliphatic amine polymer and s monovalent anion can prevent or ameliorate acidosis, in particular acidosis in patients with renal disease. The tablets and compositions of the present invention maintain a disintegration time of no greater than 30 minutes at 37° C. and at pH of at least 1 for a period of at least ten weeks at 60° C. Furthermore, the tablets are stable for extended periods of time without the need for specialized storage conditions.
    Patent expiration dates:
    • October 27, 2025
      Drug product


Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.